Syndax Pharmaceuticals (SNDX) Price & Analysis

Compare

872 Followers

SNDX Stock Chart & Stats

$19.74

$0.12(0.87%)

At close: Jan 08 4:00 PM EST

$19.74

$0.12(0.87%)

Day’s Range― - ―

52-Week Range$8.58 - $20.20

Previous CloseN/A

Volume201.89K

Average Volume (3M)3.20M

Market Cap

$1.63B

Enterprise Value$1.24B

Total Cash (Recent Filing)$454.17M

Total Debt (Recent Filing)$345.43M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Mar 09, 2026

EPS Estimate

-0.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding86,914,840

10 Day Avg. Volume2,032,062

30 Day Avg. Volume3,202,276

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)3.93

Price to Sales (P/S)47.80

P/FCF Ratio-4.12

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue11.13

Enterprise Value/Gross Profit12.06

Enterprise Value/Ebitda-4.21

Forecast

1Y Price Target

$37.50

Price Target Upside89.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.08

Revenue Forecast (FY)$167.57M

Bulls Say, Bears Say

Bulls Say

Competitive PositioningRevuforj is now the first and only menin inhibitor approved in both NPM1-mutant and KMT2A-rearranged AML, reinforcing its commercial first-mover advantage.

Market ExpansionRevuforj's label was expanded to include use in R/R NPM1 AML, which should accelerate growth.

Regulatory ApprovalThe FDA has approved Revuforj for the treatment of relapsed or refractory AML in patients with susceptible NPM1 mutations, expanding its reach into the largest AML genetic subset.

Bears Say

Investor ConcernsShares traded down approximately 8% due to investor concerns over the expanded boxed warning, though it is not viewed as a significant commercial impediment.

Safety ConcernsFDA approved the sNDA for Revuforj for R/R NPM1m AML—but notably added QTc prolongation to the Black Box.

Syndax Pharmaceuticals News

Syndax price target raised to $35 from $22 at Barclays

Barclays raised the firm’s price target on Syndax (SNDX) to $35 from $22 and keeps an Overweight rating...

12d ago

SNDX

Syndax price target lowered to $33 from $40 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $33 from $40 and keeps...

24d ago

SNDX

Syndax Pharmaceuticals: Q3 Earnings Call Highlights

Syndax Pharmaceuticals Inc. (($SNDX)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

SNDX

Syndax price target raised to $38 from $35 at UBS

UBS raised the firm’s price target on Syndax (SNDX) to $38 from $35 and keeps a Buy rating...

1M ago

SNDX

Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals

TD Cowen analyst Phil Nadeau has maintained their bullish stance on SNDX stock, giving a Buy rating today....

1M ago

SNDX

Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals and keeping the price...

1M ago

SNDX

Syndax price target raised to $22 from $19 at Barclays

Barclays analyst Peter Lawson raised the firm’s price target on Syndax (SNDX) to $22 from $19 and keeps...

1M ago

SNDX

Syndax Pharmaceuticals Reports Strong Q3 2025 Growth

Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

SNDX

Syndax reports Q3 EPS (70c), consensus (71c)

Reports Q3 revenue $45.9M, consensus $47.97M. The company reported $456.1M in cash, cash equivalents and investments, which it...

1M ago

SNDX

Syndax sees operating expense base remaining stable over next few years

For FY25, the company expects total research and development plus selling, general and administrative expenses to be $380M-$385M,...

1M ago

SNDX

Syndax options imply 10.9% move in share price post-earnings

Pre-earnings options volume in Syndax (SNDX) is normal with calls leading puts 7:5. Implied volatility suggests the market...

1M ago

SNDX

Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025

Syndax (SNDX) Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were...

1M ago

SNDX

SNDX Upcoming Earnings Report: What to Expect?

Syndax Pharmaceuticals Inc. (SNDX) is scheduled to report 3rd quarter earnings on 11/03/2025, after the market closes. Regarding...

1M ago

SNDX

Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib

Syndax Pharmaceuticals Inc. (($SNDX)) announced an update on their ongoing clinical study. In a significant development, Syndax Pharmaceuticals...

1M ago

SNDX

SNDX FAQ

What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?

Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $20.20 in the past 12 months.

What is Syndax Pharmaceuticals Inc’s market cap?

Syndax Pharmaceuticals Inc’s market cap is $1.63B.

When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?

Syndax Pharmaceuticals Inc’s upcoming earnings report date is Mar 09, 2026 which is in 93 days.

How were Syndax Pharmaceuticals Inc’s earnings last quarter?

Syndax Pharmaceuticals Inc released its earnings results on Nov 03, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.024.

Is Syndax Pharmaceuticals Inc overvalued?

According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Syndax Pharmaceuticals Inc pay dividends?

Syndax Pharmaceuticals Inc does not currently pay dividends.

What is Syndax Pharmaceuticals Inc’s EPS estimate?

Syndax Pharmaceuticals Inc’s EPS estimate is -0.59.

How many shares outstanding does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc has 86,914,840 shares outstanding.

What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?

Syndax Pharmaceuticals Inc reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 11.555%.

Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in SNDX

Syndax Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-129.32%

Trailing 12-Months

Asset Growth

29.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals (SNDX) Earnings & Revenues

Historic Earnings Reports

SNDX Company Deck

SNDX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Syndax showed strong revenue growth and successful product launches, with Revuforj expanding its market potential significantly through an FDA approval. However, temporary treatment pauses and higher gross to net adjustments posed challenges in realizing full revenue potential.View all SNDX earnings summaries

SNDX Stock 12 Month Forecast

Average Price Target

$37.50

▲(89.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","57":"$57","19.5":"$19.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.5,32,44.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,16.953846153846154,20.207692307692305,23.46153846153846,26.715384615384615,29.96923076923077,33.22307692307692,36.47692307692307,39.730769230769226,42.98461538461538,46.238461538461536,49.49230769230769,52.746153846153845,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,15.53076923076923,17.361538461538462,19.192307692307693,21.02307692307692,22.853846153846156,24.684615384615384,26.515384615384615,28.346153846153847,30.176923076923078,32.00769230769231,33.838461538461544,35.669230769230765,{"y":37.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,14.492307692307692,15.284615384615384,16.076923076923077,16.869230769230768,17.661538461538463,18.453846153846154,19.246153846153845,20.03846153846154,20.83076923076923,21.623076923076923,22.415384615384617,23.20769230769231,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >